![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SLC36A1 |
Gene summary for SLC36A1 |
![]() |
Gene information | Species | Human | Gene symbol | SLC36A1 | Gene ID | 206358 |
Gene name | solute carrier family 36 member 1 | |
Gene Alias | Dct1 | |
Cytomap | 5q33.1 | |
Gene Type | protein-coding | GO ID | GO:0003333 | UniProtAcc | Q7Z2H8 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
206358 | SLC36A1 | HTA11_347_2000001011 | Human | Colorectum | AD | 2.28e-10 | 5.20e-01 | -0.1954 |
206358 | SLC36A1 | A002-C-205 | Human | Colorectum | FAP | 8.13e-03 | -1.53e-01 | -0.1236 |
206358 | SLC36A1 | A015-C-006 | Human | Colorectum | FAP | 4.07e-04 | -2.05e-01 | -0.0994 |
206358 | SLC36A1 | A002-C-116 | Human | Colorectum | FAP | 5.03e-04 | -1.61e-01 | -0.0452 |
206358 | SLC36A1 | A014-C-008 | Human | Colorectum | FAP | 1.08e-03 | -2.05e-01 | -0.191 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:1902600 | Colorectum | AD | proton transmembrane transport | 66/3918 | 157/18723 | 1.59e-09 | 1.17e-07 | 66 |
GO:19026004 | Colorectum | FAP | proton transmembrane transport | 39/2622 | 157/18723 | 2.03e-04 | 2.92e-03 | 39 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLC36A1 | SNV | Missense_Mutation | c.950A>T | p.Asn317Ile | p.N317I | Q7Z2H8 | protein_coding | deleterious(0.02) | benign(0.278) | TCGA-35-5375-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
SLC36A1 | SNV | Missense_Mutation | c.883N>C | p.Gly295Arg | p.G295R | Q7Z2H8 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-44-3918-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD | |
SLC36A1 | SNV | Missense_Mutation | novel | c.941N>A | p.Phe314Tyr | p.F314Y | Q7Z2H8 | protein_coding | tolerated(0.19) | benign(0.25) | TCGA-44-A47B-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
SLC36A1 | SNV | Missense_Mutation | rs201241765 | c.406N>A | p.Ala136Thr | p.A136T | Q7Z2H8 | protein_coding | deleterious(0.03) | possibly_damaging(0.746) | TCGA-50-5051-01 | Lung | lung adenocarcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | PD |
SLC36A1 | SNV | Missense_Mutation | c.286G>T | p.Gly96Cys | p.G96C | Q7Z2H8 | protein_coding | tolerated(0.07) | possibly_damaging(0.759) | TCGA-53-7624-01 | Lung | lung adenocarcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | PD | |
SLC36A1 | SNV | Missense_Mutation | c.1094N>T | p.Arg365Leu | p.R365L | Q7Z2H8 | protein_coding | deleterious(0.04) | possibly_damaging(0.73) | TCGA-53-7626-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unspecific | Cisplatin | PD | |
SLC36A1 | SNV | Missense_Mutation | rs200047726 | c.1250C>T | p.Pro417Leu | p.P417L | Q7Z2H8 | protein_coding | deleterious(0.01) | probably_damaging(0.983) | TCGA-55-7726-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLC36A1 | SNV | Missense_Mutation | novel | c.1180C>T | p.Pro394Ser | p.P394S | Q7Z2H8 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-21-1079-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
SLC36A1 | SNV | Missense_Mutation | novel | c.850N>A | p.Asp284Asn | p.D284N | Q7Z2H8 | protein_coding | tolerated(0.56) | benign(0.013) | TCGA-94-8491-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | unknown | PD |
SLC36A1 | SNV | Missense_Mutation | novel | c.810N>T | p.Glu270Asp | p.E270D | Q7Z2H8 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-96-8170-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
206358 | SLC36A1 | EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER | inhibitor | 135651515 | TRYPTOPHAN | |
206358 | SLC36A1 | EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER | inhibitor | 135651413 | SEROTONIN | |
206358 | SLC36A1 | EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER | inhibitor | 178101420 | ||
206358 | SLC36A1 | EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER | inhibitor | 178101386 | OXITRIPTAN |
Page: 1 |